Professional Disposables International, Inc.
Letter data
- Company
- Professional Disposables International, Inc.
- Recipient
- Mr. Zachary Julius | CEO | Professional Disposables International, Inc. | 4855 Pine Tree Drive | Miami Beach | , | FL | 33140 | United States
- Issue date
- 2024-12-05
- Posted date
- Not available
- FDA office
- Division of Pharmaceutical Quality Operations I
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 617201
- Reference number
- Not available
- FEI
- 2411192
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Professional Disposables International, Inc.
MARCS-CMS 617201 —
December 05, 2024
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Reference #:
FEI 2411192
Product:
Drugs
Recipient:
Recipient Name
Mr. Zachary Julius
Recipient Title
CEO
Professional Disposables International, Inc.
4855 Pine Tree Drive
Miami Beach
,
FL
33140
United States
Issuing Office:
Division of Pharmaceutical Quality Operations I
United States
Secondary Issuing Offices
United States
Dear Mr. Julius:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 617201 dated January 07, 2022.
Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter pertaining to Professional Disposables International, Inc., FEI 2411192. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.
The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Emmanuel Ramos
Compliance Officer
Division of Drug Quality III
Office of Manufacturing Quality
Content current as of:
12/12/2024
Regulated Product(s)
Drugs